Escient Pharmaceuticals, Inc.
3033 Science Park Road, Ste 230
About Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals is a biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. We are focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs), and will initially pursue medicines for neuro-immuno-inflammatory and autoreactive diseases.
Based in San Diego, we are led by an experienced team of entrepreneurs with deep roots in this region’s life sciences ecosystem and specific expertise in GPCR drug discovery and development. Escient Pharmaceuticals is supported by top-tier life-sciences investors with a proven track record for identifying and supporting successful, next-generation medicines companies.
4 articles with Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritus
Sept. 14, 2020 13:00 UTC -- Proceeds support clinical development for lead program in cholestatic and uremic pruritus and second program for mast cell-related diseases -- Financing round led by Sanofi Ventures and Cowen Healthcare Investments and included new investors Redmile Group and Perceptive Advisors -- Jason Hafler, Ph.D., of Sanofi Ventures and Kevin Raidy of Cowen Healthcare Investments join Escient board of directors SAN DIEGO--( BUSINESS WIRE )-- Es
Eurofins Discovery provides premier, integrated drug discovery services for the pharma and biotech industry
Escient Pharmaceuticals, Inc., a biotechnology company advancing first-in-class G Protein Coupled Receptor (GPCR)-targeted drugs to address unmet needs for a broad range of therapeutic indications, today announced the appointment of K. Peter Hirth to its Board of Directors
Escient Pharmaceuticals Appoints Kristin Taylor, PhD as Vice President and Head of Clinical Development
Seasoned industry leader to steer Escient’s clinical development and regulatory strategies as it advances first-in-class Mrgpr-focused pipeline